Electronic Supplementary Material (ESI) for New Journal of Chemistry.

Surporting Information

Reduction-responsive and tumour-targeted polyprodrug nanocarriers for targeting therapy of hepatocellular carcinoma

Wei Shi,[a] XiaoQing Xu,[a] JinYuan Tian,[a] ZiYi Zhang[a] and ZhanJun Liu*[a]

a. School of Pharmacy, North China University of Science and Technology, Tangshan 063210, China.

E-mail address of Corresponding author: liuzhanjun@ncst.edu.cn

1.Table S1 Nanoparticle size, PDI, zeta potential and critical aggregation concentration (CAC) affected by HA-SS-PFA at different ratios

HA-SS@PFA	Size (nm)	Zeta (mV)	PDI	CAC ($mg \cdot mL^{-1}$)
2:1	247.4±4.1	-23.45±0.23	0.432±0.023	0.0821
1:1	163.4±3.2	-25.61±0.35	0.255±0.014	0.0604
1:2	145.4±2.8	-27.70±0.12	0.195±0.064	0.0589
1:3	178.9±3.6	-19.13±0.74	0.188±0.042	0.0642
1:4	220.2±1.5	-20.43±0.63	0.367±0.031	0.0974

2. The content of DOX in nano-preparation was determined by HPLC.

Chromatographic conditions: Diamonsil C18 column (250 mm × 4.6 mm, 5.0 μm); mobile phase: acetonitrile–2% glacial acetic acid solution (v/v = 35/65); flow rate: 1.0 $mL \cdot min^{-1}$; UV detection wavelength: 481 nm; sample size: 20 μL; column temperature: 30°C.

3. Zeta potential graphs of HA-SS-PFA NPs (a) and DOX@HA-SS-PFA NPs (b).





4. Critical aggregation concentration (CAC) of HA-SS-PFA NPs.